15.75

5.21% +0.78

Pre-market: 16.05 0.30 +1.90%

Immunome Inc (IMNM)

Overview News Price History Option Chain Financials Discussions Forecast

Immunome Inc stock is currently priced at $15.75, with a 24-hour trading volume of 728.63K. It has seen a +5.21% increased in the last 24 hours and a -27.08% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $14.79 pivot point. If it approaches the $15.83 resistance level, significant changes may occur.

Previous Close:

$14.97

Open:

$15.26

24h Volume:

728.63K

Market Cap:

$944.11M

Revenue:

Net Income/Loss:

$-106.81M

P/E Ratio:

-7.1591

EPS:

-2.2

Net Cash Flow:

$-8.40M

1W Performance:

+14.71%

1M Performance:

-27.08%

6M Performance:

+80.00%

1Y Performance:

+209.43%

1D Range:

$15.10

$16.05

52W Range:

$4.50

$30.96

Immunome Inc Stock (IMNM) Company Profile

Name

Immunome Inc

Sector

Healthcare (1213)

Industry

Biotechnology (699)

Phone

610 321 3700

Address

665 Stockton Drive, Suite 300, Exton

Employee

Twitter

Next Earnings Date

2024-05-03

Latest SEC Filings

IMNM's Discussions on Twitter

Immunome Inc Stock (IMNM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-29-21	Initiated	Cantor Fitzgerald	Overweight

Immunome Inc Stock (IMNM) Latest News

Analysts Estimate Immunome, Inc. (IMNM) to Report a Decline in Earnings: What to Look Out for

Zacks Investment Research

New Strong Sell Stocks for April 4th

Zacks Investment Research

Company News for Apr 2, 2024

Zacks Investment Research

Stocks Pause As Traders Reassess Interest Rate Path, Gold Makes New Highs, Bitcoin Rebounds: What's Driving Markets Thursday?

Benzinga

Worthington Steel Posts Upbeat Results, Joins Summit Midstream Partners, FedEx And Other Big Stocks Moving Higher On Friday

Benzinga

Biotech Stocks Surge To Start 2024: 'Charts Look Great,' But Will The Trend Continue?

Benzinga

Immunome Inc Stock (IMNM) Financials Data

Immunome Inc (IMNM) Net Income 2024

IMNM net income (TTM) was -$106.81 million for the quarter ending December 31, 2023, a -189.48% decrease year-over-year.

Immunome Inc (IMNM) Cash Flow 2024

IMNM recorded a free cash flow (TTM) of -$8.40 million for the quarter ending December 31, 2023, a +70.98% increase year-over-year.

Immunome Inc (IMNM) Earnings per Share 2024

IMNM earnings per share (TTM) was -$3.3117 for the quarter ending December 31, 2023, a -7.17% decline year-over-year.

Immunome Inc Stock (IMNM) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Turner Bruce	Chief Strategy Officer	Oct 02 '23	Buy	5.91	42,300	249,993	42,300

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.